Showing 1 - 2 results of 2 for search 'S. N. Fogt', query time: 0.01s Refine Results
  1. 1
    IS IT POSSIBLE TO USE BEVACIZUMAB BIOSIMILAR IN ALL INDICATIONS REGISTERED FOR ORIGINAL DRUG?

    IS IT POSSIBLE TO USE BEVACIZUMAB BIOSIMILAR IN ALL INDICATIONS REGISTERED FOR ORIGINAL DRUG? by S. V. Orlov, N. L. Shimanovskii, S. N. Fogt

    Published 2016-06-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)

    Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria) by M. Yu. Fedyanin, A. V. Snegovoy, V. V. Breder, Yu. N. Linkova, A. V. Zinkina-Orikhan, S. B. Setkina, S. N. Fogt, V. S. Chistiakov, N. A. Kravtsova

    Published 2023-06-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: